On behalf of the Board I am pleased to welcome you to the 2014 Annual General Meeting of Regeneus, our second meeting as a publicly listed company.
Let me introduce my fellow Directors. To my right, Professor Graham Vesey, our CEO and co-founder; next to Graham is Dr Roger Aston, then Barry Sechos and lastly Associate Professor Ben Herbert, also a Regeneus co-founder.
Together with the company’s committed and capable management and staff, the Board is intent on realising Regeneus’ full potential, not only to deliver significant benefits to both human and animal health but also to justify shareholders’ faith in Regeneus through enhancing the value of your investment in the company.
The Year in Review and FY15 Activity
This afternoon I will focus on the highlights of the past year’s operational activities and share with you our plans for the future and specific goals for FY15 and beyond in a slide presentation which has been lodged on the ASX Markets Announcement Platform immediately prior to this meeting.
On behalf of the Board I thank the Regeneus executive management group and all of our employees and R&D partners for their hard work and passion over the past year. We all know that we are achieving something really important at Regeneus and we look forward to another year of building revenues, developing and launching products and passing more milestones.
Finally, may I thank you, our shareholders, for your continued support and commitment to the development of regenerative medicine.